» Articles » PMID: 38098458

Discovery of Molecular Glue Degraders Via Isogenic Morphological Profiling

Abstract

Molecular glue degraders (MGDs) are small molecules that degrade proteins of interest via the ubiquitin-proteasome system. While MGDs were historically discovered serendipitously, approaches for MGD discovery now include cell-viability-based drug screens or data mining of public transcriptomics and drug response datasets. These approaches, however, have target spaces restricted to the essential proteins. Here we develop a high-throughput workflow for MGD discovery that also reaches the nonessential proteome. This workflow begins with the rapid synthesis of a compound library by sulfur(VI) fluoride exchange chemistry coupled to a morphological profiling assay in isogenic cell lines that vary in levels of the E3 ligase CRBN. By comparing the morphological changes induced by compound treatment across the isogenic cell lines, we were able to identify as a CRBN-dependent MGD targeting the nonessential protein GSPT2. We envision that this workflow would contribute to the discovery and characterization of MGDs that target a wider range of proteins.

Citing Articles

Extrapolating Lessons from Targeted Protein Degradation to Other Proximity-Inducing Drugs.

Winter G ACS Chem Biol. 2024; 19(10):2089-2102.

PMID: 39264973 PMC: 11494510. DOI: 10.1021/acschembio.4c00191.


Alkylamine-tethered molecules recruit FBXO22 for targeted protein degradation.

Kagiou C, Cisneros J, Farnung J, Liwocha J, Offensperger F, Dong K Nat Commun. 2024; 15(1):5409.

PMID: 38926334 PMC: 11208438. DOI: 10.1038/s41467-024-49739-3.


Morphological profiling for drug discovery in the era of deep learning.

Tang Q, Ratnayake R, Seabra G, Jiang Z, Fang R, Cui L Brief Bioinform. 2024; 25(4).

PMID: 38886164 PMC: 11182685. DOI: 10.1093/bib/bbae284.


Targeted protein degradation in CNS disorders: a promising route to novel therapeutics?.

Kuemper S, Cairns A, Birchall K, Yao Z, Large J Front Mol Neurosci. 2024; 17:1370509.

PMID: 38685916 PMC: 11057381. DOI: 10.3389/fnmol.2024.1370509.


SuFEx-based chemical diversification for the systematic discovery of CRBN molecular glues.

Carter T, Milosevich N, Dada L, Shaum J, Sharpless K, Kitamura S Bioorg Med Chem. 2024; 104:117699.

PMID: 38608634 PMC: 11195152. DOI: 10.1016/j.bmc.2024.117699.


References
1.
Guo T, Meng G, Zhan X, Yang Q, Ma T, Xu L . A New Portal to SuFEx Click Chemistry: A Stable Fluorosulfuryl Imidazolium Salt Emerging as an "F-SO +" Donor of Unprecedented Reactivity, Selectivity, and Scope. Angew Chem Int Ed Engl. 2017; 57(10):2605-2610. DOI: 10.1002/anie.201712429. View

2.
Bekes M, Langley D, Crews C . PROTAC targeted protein degraders: the past is prologue. Nat Rev Drug Discov. 2022; 21(3):181-200. PMC: 8765495. DOI: 10.1038/s41573-021-00371-6. View

3.
Schneider M, Radoux C, Hercules A, Ochoa D, Dunham I, Zalmas L . The PROTACtable genome. Nat Rev Drug Discov. 2021; 20(10):789-797. DOI: 10.1038/s41573-021-00245-x. View

4.
Bray M, Gustafsdottir S, Rohban M, Singh S, Ljosa V, Sokolnicki K . A dataset of images and morphological profiles of 30 000 small-molecule treatments using the Cell Painting assay. Gigascience. 2017; 6(12):1-5. PMC: 5721342. DOI: 10.1093/gigascience/giw014. View

5.
Farnaby W, Koegl M, McConnell D, Ciulli A . Transforming targeted cancer therapy with PROTACs: A forward-looking perspective. Curr Opin Pharmacol. 2021; 57:175-183. DOI: 10.1016/j.coph.2021.02.009. View